Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Model-Strengthened Imaging Biomarker for Survival Prediction in EGFR-Mutated Non-small-cell Lung Carcinoma Patients Treated with Tyrosine Kinase Inhibitors.

Bulletin of mathematical biology - 8 May 2021

Collin Annabelle, Groza Vladimir, Missenard Louise, Chomy François, Colin Thierry, Palussière Jean, Saut Olivier

Abstract excerpt

Non-small-cell lung carcinoma is a frequent type of lung cancer with a bad prognosis. Depending on the stage and genomics, several therapeutical approaches are used. Tyrosine Kinase Inhibitors (TKI) may be successful for a time in the treatment of EGFR-mutated non-small cells lung carcinoma. Our objective is here to introduce a survival assessment as their efficacy in the long run is challenging to evaluate. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Models, Theoretical

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Survival Analysis

Source

Identifiers

PMID: 33966172
DOI: 10.1007/s11538-021-00902-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Model-Strengthened Imaging Biomarker for Survival Prediction in EGFR-Mutated Non-small-cell Lung Carcinoma Patients Treated with Tyrosine Kinase Inhibitors.PMID 33966172Read ↗

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to in-Vivo ImagesSemantic proximity Read ↗

Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy.Semantic proximity Read ↗

Topological radiogenomics based on persistent lifetime images for identification of epidermal growth factor receptor mutation in patients with non-small cell lung tumors.Semantic proximity Read ↗

A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy.Semantic proximity Read ↗

Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer.Semantic proximity Read ↗

Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS.Semantic proximity Read ↗

Identifying relationships between imaging phenotypes and lung cancer-related mutation status: <i>EGFR</i> and <i>KRAS</i>Semantic proximity Read ↗

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.Semantic proximity Read ↗

Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic.Semantic proximity Read ↗

CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients.Semantic proximity Read ↗

Ensemble Strategies for EGFR Mutation Status Prediction in Lung Cancer.Semantic proximity Read ↗

Prediction Models of Tumor Growth Trajectories Based on Pretreatment CT Images of TKI-Treated Lung Cancer PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.